| Model input | ICER (EUR) | ||
---|---|---|---|---|
Base case | Sensitivity | Sweden | Norway | |
Base case | Â | Â | 18,506 | 19,954 |
Analyses of structural changes and altering assumptions | ||||
 Indirect costs | Not included | Included | Dominating | Dominating |
 Discount rate costs and health effects | 3% (Sweden) and 4% (Norway) | 0% | 17,931 | 19,250 |
5% | 18,893 | 20,132 | ||
 Stopping rule | 30% reduction in 2 cycles | No stopping rule | 23,412 | 24,545 |
50% reduction in 2 cycles | 17,666 | 19,163 | ||
0% reduction in 2 cycles | 21,825 | 23,070 | ||
 Population | All patients | ≥1 prior prophylactic | 15,160 | 16,900 |
≥3 prior prophylactics | 15,764 | 17,532 | ||
 Utilities | Estimated from COI database | REPOSE [56] | 14,565 | 15,702 |
15,634 | 16,804 | |||
IBMS | 18,219 | 19,644 | ||
 Time horizon | 10 years | 5 years | 21,481 | 22,645 |
Analysis mirroring previous erenumab analysis | ||||
 Norwegian (NOMA) and Swedish (TLV) erenumab analyses: 10-year time horizona, indirect costs not included, ≥3 prior prophylacticsb, stopping rule 30% reduction in 2 cycles, utilities mapped from MSQ to EQ-5Dc | 16,625 | 18,462 |